Business
business

“Joker: Folie à Deux” is a flop. That’s the latest setback for Warner Bros. Discovery

The much-anticipated sequel to 2019’s box office hit "Joker,” has left producers with little to laugh about, after taking just $40 million at the domestic box office. The weekend’s haul missed forecasts for a $50-60 million opening — expectations that had been continually downgraded in the lead-up to the movie’s release.

That’s less than half of what the original film managed ($96 million), despite costing triple what the first effort did, and it marks the latest misstep for WBD.

The entertainment giant has seen its shares dive 25% in the last year, considerably worse than many of its largest competitors like Netflix (+91%), Disney (+21%), and Paramount Global (-11%), as concerns about its long-term strategy intensify.

Warner Bros. stock underperformance
Sherwood News

In August, the company — which owns brands like CNN, Discovery Channel, the Food Network, HBO, and more — wrote down the value of its TV networks by $9 billion, as traditional cable continues to battle cord-cutting and the rise of streaming. Earlier this year, WBD dropped its pursuit of a potential merger with Paramount Global.

That’s less than half of what the original film managed ($96 million), despite costing triple what the first effort did, and it marks the latest misstep for WBD.

The entertainment giant has seen its shares dive 25% in the last year, considerably worse than many of its largest competitors like Netflix (+91%), Disney (+21%), and Paramount Global (-11%), as concerns about its long-term strategy intensify.

Warner Bros. stock underperformance
Sherwood News

In August, the company — which owns brands like CNN, Discovery Channel, the Food Network, HBO, and more — wrote down the value of its TV networks by $9 billion, as traditional cable continues to battle cord-cutting and the rise of streaming. Earlier this year, WBD dropped its pursuit of a potential merger with Paramount Global.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.